Effectiveness of dog rabies vaccination programmes: comparison of owner-charged and free vaccination campaigns.

We investigated the percentage of dogs that could be vaccinated against rabies by conducting a pilot campaign in N'Djaména, Chad. Owners were charged US$4.13 per dog vaccinated, and 24% of all dogs in the three city districts covered by the campaign were vaccinated. Total campaign costs were US$7623, resulting in an average of US$19.40 per vaccinated dog. This is five times more expensive than the cost per animal vaccinated during a previous free vaccination campaign for dog-owners, conducted in the same districts. The free campaign, which vaccinated 2605 more dogs than this campaign, cost an additional US$1.45 per extra dog vaccinated. Campaigns in which owners are charged for vaccinations result in lower vaccination rates than in free campaigns. Public health officials can use these results when evaluating the costs and benefits of subsidizing dog rabies vaccination programmes.

Modeling potential responses to smallpox as a bioterrorist weapon.

We constructed a mathematical model to describe the spread of smallpox after a deliberate release of the virus. Assuming 100 persons initially infected and 3 persons infected per infectious person, quarantine alone could stop disease transmission but would require a minimum daily removal rate of 50% of those with overt symptoms. Vaccination would stop the outbreak within 365 days after release only if disease transmission were reduced to <0.85 persons infected per infectious person. A combined vaccination and quarantine campaign could stop an outbreak if a daily quarantine rate of 25% were achieved and vaccination reduced smallpox transmission by > or = 33%. In such a scenario, approximately 4,200 cases would occur and 365 days would be needed to stop the outbreak. Historical data indicate that a median of 2,155 smallpox vaccine doses per case were given to stop outbreaks, implying that a stockpile of 40 million doses should be adequate.

Introduction to health economics for physicians.

Since the 1960s, expenditure on health care in developed countries has risen faster than the general rate of inflation, thus making economic assessment of interventions an integral part of decision making in health services. This paper is the first in a series whose goal is to provide some basic principles of health economics that will allow practising physicians to understand better the economic relations between their practice of medicine, the health-care sector, and the national economy. Some of the most important principles described in this paper include opportunity costs, identifying the appropriate perspective, correctly categorising costs, and discounting costs and non-monetary benefits (eg, lives saved) over time. Economic analyses of medical interventions must also take into consideration the difference between efficacy and effectiveness. Efficacy is the maximum possible benefit, often achieved with carefully controlled trials, and effectiveness is the actual decrease in disease achieved when the intervention is applied over a large, non-homogeneous population. This introduction ends with three methods of assessing the costs and benefits of an intervention-namely, cost-benefit, cost-effectiveness, and cost-utility analyses.

The economics of vaccinating restaurant workers against hepatitis A.

The economics of vaccinating restaurant workers against hepatitis A were studied using Monte Carlo simulation models, one with a restaurant-owner perspective, and one with a societal perspective. The restaurant model allowed for a different size, number of employees and employee turnover rate. Benefits were the avoidance of loss of business (including the possibility of bankruptcy) after publicity linking the restaurant to an outbreak associated with a case of hepatitis A in a food handler. Additional benefits in the societal model included reductions in costs of food handler-associated cases of hepatitis A. The outcome used was Net Present Value (NPV), allowing comparison between models. Regardless of the cost of vaccination ($50-140/employee), for a restauranteur to ensure that all employees were vaccinated at all times substantial costs were involved (i.e. negative NPV). Even a 75% probability of bankruptcy still resulted in negative NPVs at the 95th percentiles. For society, vaccination was only cost-saving (i.e. positive NPV) if done only during epidemics and if it cost < $20/employee. Vaccinating restaurant employees is unlikely to be economical from either the restaurant owner or the societal perspective, even during hepatitis A epidemics.

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

CONTEXT: Although the cost-effectiveness and cost-benefit of influenza vaccination are well established for persons aged 65 years or older, the benefits for healthy adults younger than 65 years are less clear. OBJECTIVE: To evaluate the effectiveness and cost-benefit of influenza vaccine in preventing influenza-like illness (ILI) and reducing societal costs of ILI among healthy working adults. DESIGN: Double-blind, randomized, placebo-controlled trial conducted during 2 influenza seasons. SETTING AND PARTICIPANTS: Healthy adults aged 18 to 64 years and employed full-time by a US manufacturing company (for 1997-1998 season, n = 1184; for 1998-1999 season, n = 1191). INTERVENTIONS: For each season, participants were randomly assigned to receive either trivalent inactivated influenza vaccine (n = 595 in 1997-1998 and n = 587 in 1998-1999) or sterile saline injection (placebo; n = 589 in 1997-1998 and n = 604 in 1998-1999). Participants in 1997-1998 were rerandomized if they participated in 1998-1999. MAIN OUTCOME MEASURES: Influenza-like illnesses and associated physician visits and work absenteeism reported in biweekly questionnaires by all participants, and serologically confirmed influenza illness among 23% of participants in each year (n = 275 in 1997-1998; n = 278 in 1998-1999); societal cost of ILI per vaccinated vs unvaccinated person. RESULTS: For 1997-1998 and 1998-1999, respectively, 95% (1130/1184) and 99% (1178/1191) of participants had complete follow-up, and 23% in each year had serologic testing. In 1997-1998, when the vaccine virus differed from the predominant circulating viruses, vaccine efficacy against serologically confirmed influenza illness was 50% (P =.33). In this season, vaccination did not reduce ILI, physician visits, or lost workdays; the net societal cost was $65.59 per person compared with no vaccination. In 1998-1999, the vaccine and predominant circulating viruses were well matched. Vaccine efficacy was 86% (P =.001), and vaccination reduced ILI, physician visits, and lost workdays by 34%, 42%, and 32%, respectively. However, vaccination resulted in a net societal cost of $11.17 per person compared with no vaccination. CONCLUSION: Influenza vaccination of healthy working adults younger than 65 years can reduce the rates of ILI, lost workdays, and physician visits during years when the vaccine and circulating viruses are similar, but vaccination may not provide overall economic benefits in most years. JAMA. 2000;284:1655-1663.

Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.

OBJECTIVE: To compare the economic costs and benefits associated with using either diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) or diphtheria and tetanus toxoids and whole-cell pertussis vaccine (DTwP) in the United States in 1997. DESIGN: Standard cost-benefit analysis, from both the societal and health care system perspectives, was performed for each combination vaccine as well as for the pertussis components singly. SETTING: A simulated cohort of 4.1 million children from birth to age 15 years. MAIN OUTCOME MEASURES: Net costs (savings) and benefit-cost ratios (BCRs) RESULTS: Without a vaccination program, diphtheria, tetanus, and pertussis disease caused more than 3 million cases and more than 28,000 deaths, at a cost of $23.6 billion. From the societal perspective, net savings because of the use of DTaP and DTwP were $22.510 million and $22.623 million, respectively. The net savings from the acellular pertussis component and the whole-cell pertussis component only were $4.362 million and $4.474 million, respectively. Benefit-cost ratios for DTaP from a societal and health care system perspective were 27:1 and 9:1, respectively. Sensitivity analyses of key variables did not result in appreciable changes in results. CONCLUSIONS: Compared with no program, vaccination with DTaP or DTwP resulted in substantial savings, regardless of the perspective taken and for all sensitivity analyses conducted. Compared with DTwP, use of DTaP generated a small cost increase that might be offset by the value of other factors, such as increased confidence in pertussis vaccination resulting from reduced adverse events. Arch Pediatr Adolesc Med. 2000;154:797-803

Costs and benefits of a subtype-specific surveillance system for identifying Escherichia coli O157:H7 outbreaks.

We assessed the societal costs and benefits of a subtype-specific surveillance system for identifying outbreak-associated Escherichia coli O157:H7 infections. Using data from Colorado, we estimated that if it averted five cases annually, the system would recover all its costs.

The economic impact of pandemic influenza in the United States: priorities for intervention.

We estimated the possible effects of the next influenza pandemic in the United States and analyzed the economic impact of vaccine-based interventions. Using death rates, hospitalization data, and outpatient visits, we estimated 89,000 to 207,000 deaths; 314,000 to 734,000 hospitalizations; 18 to 42 million outpatient visits; and 20 to 47 million additional illnesses. Patients at high risk (15% of the population) would account for approximately 84% of all deaths. The estimated economic impact would be US$71.3 to $166.5 billion, excluding disruptions to commerce and society. At $21 per vaccinee, we project a net savings to society if persons in all age groups are vaccinated. At $62 per vaccinee and at gross attack rates of 25%, we project net losses if persons not at high risk for complications are vaccinated. Vaccinating 60% of the population would generate the highest economic returns but may not be possible within the time required for vaccine effectiveness, especially if two doses of vaccine are required.

The effect of subclinical experimental Cowdria ruminantium infection on the health and reproductive performance of breeding ewes.

This study documented the effect on the productivity of Dorper-Merino cross ewes when they became infected with Cowdria ruminantium as would occur in an endemically stable state. A flock of 152 breeding ewes was randomly divided into two matched groups. One group was infected on multiple occasions with C. ruminantium; the other group remained uninfected. The ewes were bred and monitored for one breeding/lambing/weaning cycle. Hematological, reproductive, and health parameters were recorded at regular intervals. Statistically significant differences in hematological values between the two groups were infrequent and transient. No significant differences in weights, mortality rates or reproductive parameters were detected between the two groups. Subclinical C. ruminantium infection did not negatively affect health and reproductive performance of breeding ewes; endemic stability would be a suitable alternative method of controlling heartwater.

The effect of subclinical experimental Cowdria ruminantium infection in ewes on the growth and milk consumption of pre-weaning lambs.

An alternative control option for heartwater (Cowdria ruminantium infection) is the establishment and maintenance of endemic stability which would lessen the existing dependence on acaricides. In an endemically stable state, animals become infected by vaccination or natural challenge at an early age, following which the immunity so created is boosted by continuing tick challenge. In this study, growth rates, health and hematological parameters were monitored at regular intervals for lambs born to two matched groups of ewes until weaning at 4 mo of age. One group of ewes was infected multiple times with Cowdria ruminantium; the other group remained uninfected. The overall mean leucocyte count of lambs born to infected ewes was significantly lower than that of lambs born to uninfected ewes (P=0.04). However, there were few other significant differences in the other hematological data between the two groups. The mean birth weight of single lambs born to uninfected ewes (4.6 kg) was significantly higher than the mean birth weight of single lambs born to infected ewes (4.4 kg) (P=0.02). Trends in milk consumption and growth rates were similar for the two groups, with few significant differences detected. Likewise, there were no significant differences in the incidences of health problems or pre-weaning mortalities between the two groups of lambs. The results of this study indicate that there is no detectable effect on productivity of pre-weaning lambs when their dams are carriers of C. ruminantium--a situation likely to occur in an endemically stable state. Hence, maintenance of endemic stability would be a suitable control option for heartwater.

The cost effectiveness of vaccinating against Lyme disease.

To determine the cost effectiveness of vaccinating against Lyme disease, we used a decision tree to examine the impact on society of six key components. The main measure of outcome was the cost per case averted. Assuming a 0.80 probability of diagnosing and treating early Lyme disease, a 0.005 probability of contracting Lyme disease, and a vaccination cost of $50 per year, the mean cost of vaccination per case averted was $4,466. When we increased the probability of contracting Lyme disease to 0.03 and the cost of vaccination to $100 per year, the mean net savings per case averted was $3,377. Since few communities have average annual incidences of Lyme disease >0. 005, economic benefits will be greatest when vaccination is used on the basis of individual risk, specifically, in persons whose probability of contracting Lyme disease is >0.01.

Models for heartwater epidemiology: practical implications and suggestions for future research.

We present a simple model of the dynamics of heartwater that we use to explore and better understand various aspects of this disease. We adapted the Ross-Macdonald model for malaria epidemiology so that we could consider both host and vector populations, and evaluate the interactions between the two. We then use two more biologically detailed models to examine heartwater epidemiology. The first includes a carrier state and host mortality, and the second includes density dependence. The results from all three models indicate that a stable equilibrium with high disease levels is probably the standard situation for heartwater (R0 between 5.7 and 22.4). More than 80% of cattle become infected with heartwater if only 12% of infected tick bites produce an infection in cattle, if tick burdens are as low as only five ticks per host per day, or if tick lifespans are as short as 7 d. A host recovery rate of 30 d results in over 50% of the cattle becoming infected with heartwater. Our analyses indicate that it is quite difficult to prevent the establishment and maintenance of high levels of heartwater in a herd, thereby supporting previous suggestions that any attempts at controlling this disease through stringent tick control regimens are not warranted.

Using disability-adjusted life years to assess the economic impact of dengue in Puerto Rico: 1984-1994.

This study presents the disability-adjusted life years (DALYs), a non-monetary economic measure of impact, lost to dengue in Puerto Rico for the period 1984-1994. Data on the number of reported cases, cases with hemorrhagic manifestations, hospitalizations, and deaths were obtained from a surveillance system maintained at the Dengue Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention (San Juan, PR). The reported cases were divided into two age groups (0-15 years old and >15 years old), and then multiplied by predetermined factors (10 for 0-15 years; 27 for >15 years) to allow for age-related under-reporting of cases. Severity of dengue was modeled by classifying cases into three groups: dengue fever, dengue with severe manifestations, and hospitalized cases. Each group was assigned a different number of days lost because of dengue-related disability. Dengue caused an average of 658 DALYs per year per million population (SE = 114, range = 145-1,519). A multivariate sensitivity analysis, which simultaneously altered the values of six input variables, produced a mean of 580 DALYs/year/million population, with a maximum average of 1,021 DALYs/year/million population, and a maximum, single-year estimate for 1994 of 2,153 DALYs/million population. The most important input was the number of days lost to classic dengue. The DALYs/year/million population lost to dengue in Puerto Rico are much greater than previous estimates concerning the impact of dengue hemorrhagic fever alone. The loss to dengue is similar to the losses per million population in the Latin American and Caribbean region attributed to any of the following diseases or disease clusters; the childhood cluster (polio, measles, pertussis, diphtheria, tetanus), meningitis, hepatitis, or malaria. The loss is also of the same order of magnitude as any one of the following: tuberculosis, sexually transmitted diseases (excluding human immunodeficiency virus), tropical cluster (e.g., Chagas' disease, leishmaniasis), or intestinal helminths. The results objectively suggest that when governments and international funding agencies allocate resources for research and control, dengue should be given a priority equal to many other infectious diseases that are generally considered more important.

Glaucoma's impact on quality of life and its relation to clinical indicators. A pilot study.

OBJECTIVE: This study aimed to compare the quality of life (Q of L) of patients with glaucoma and control subjects and to determine the relationships between Q of L and demographic and clinical variables in patients with glaucoma. DESIGN: The study design was a stratified cross-sectional study. PARTICIPANTS: A gender-, race-, and age-stratified cross-sectional sample of patients with glaucoma (n = 56) and control subjects (n = 54) was obtained. Additional patients (n = 12) were included to examine the relationships between glaucoma, its therapy, and Q of L. INTERVENTION: The Medical Outcomes Study short form (MOS-20), the Activities of Daily Vision Scale (ADVS), and questions related to glaucoma and side effects of treatment were administered. Descriptive statistics characterized demographic variables and MOS and ADVS scales. Group differences were evaluated using chi-square, Fisher's and Ordinal Exact, Wilcoxon rank-sum, and two-sample t tests. Spearman rank correlations were obtained between MOS-ADVS scores and clinical and demographic variables. Regression was used for multivariate analysis. MAIN OUTCOME MEASURES: The MOS scores, ADVS scores, visual acuity, visual fields, and demographic variables were measured. RESULTS: Patients scored significantly lower than did the control subjects in all MOS-20 categories except pain. Differences were physical (-20%), role (-43%), mental health (-10%), general health (-22%), and social (-9%). The only category that was not statistically significant was that of pain (P = 0.075). In the glaucoma subgroup, there were differences between whites and nonwhites in MOS subscales physical, role, social, pain, and health, and ADVS near vision. In patients, current medications and previous surgeries correlated with ADVS subscales night vision, near vision, and glare; visual acuity and fields correlated with MOS subscales physical, role and health, and all ADVS subscales. A multiple regression model including visual acuity and fields, urban residence, and female gender explained 61% of the variability in ADVS overall score. CONCLUSIONS: The Q-of-L perception differed between patients with glaucoma and control subjects. Increasing field loss, decreased visual acuity, and complexity of therapy correlated with patients' reduction in activities of daily vision.

A review of the economics of the prevention and control of rabies. Part 1: Global impact and rabies in humans.

The existing literature on the economics of rabies and its control can be characterised as a poorly documented set of cost estimates with insufficient information to allow replication of the analyses. Most articles have numerous 'violations' of the standard recommended procedures for assessing the burden of disease and the cost and benefits of interventions. Per capita costs are often crudely extrapolated from small to large populations without allowing for geographic differences in incidence. Furthermore, most studies do not distinguish between financial charges and true economic costs, and only a few articles contain a multiyear framework, complete with discounting of future costs and benefits. With the exception of the increase in average incidence of postexposure prophylaxes (PEPs) in Asia, the average incidences of both human-rabies cases and PEPs in Africa, the Americas and Europe have not changed significantly over time. There are, however, large differences between countries within a region and regional averages can conceal notable changes in incidences over time for a given country. The largest number of human-rabies cases occur in developing countries due to the low levels of vaccination among dogs, the high cost of biologicals for PEP and problems of availability. The costs (1995 values) of PEP range from $US1707 per person in Massachusetts, US, to $US2.50 for a complete series of vaccinations (without immunoglobulin) using sheep-derived vaccines in Karachi, Pakistan. Most studies which reported the cost of PEP, however, provided only direct medical costs and did not consider indirect costs such as lost productivity due to death, permanent disability or time spent while receiving medical care. Given the expense of controlling rabies in dogs and wildlife, there is an urgent need to develop a cheaper human-rabies vaccine or further refine the 'low-dose' PEP regimes. PEP is often given unnecessarily, and experience with expert consultations systems and algorithms has shown that the rate, and therefore total cost, of PEP can be significantly reduced. However, because it may be difficult to identify lesions from a bite by a bat, algorithms may be of less value when dealing with possible exposure to bat rabies. Using US prices and values, only 2 individuals per 1000 possible contacts have to be at risk from bat rabies in order for it to be economically justifiable to give PEP to all those potentially exposed to bat rabies. With regard to pre-exposure vaccination, routine use of pre-exposure has generally not been shown to be cost effective.

A review of the economics of the prevention and control of rabies. Part 2: Rabies in dogs, livestock and wildlife.

Although rabies in domestic and wild animals represents a significant threat to public health and can cause economic losses among livestock, there are very few studies that examine the economics of rabies in animals. The literature that does exist can be characterised as poorly documented estimates of costs, with insufficient information to allow replication of the analyses. Most papers have numerous 'violations' of the standard recommended procedures for assessing burden of disease and the cost and benefits of interventions. For example, most studies do not distinguish between financial charges and true economic costs. Further, despite the fact that controlling rabies in animal populations is often a multi-year task, only a few papers contain a multi-year framework, complete with discounting of future costs and benefits. Globally, dog-transmitted rabies represents the largest threat to human health. In order to prevent the transmission of rabies in a dog population, it is theoretically necessary to vaccinate a minimum of 60 to 70% of the dogs. Even countries with potentially sufficient resources, however, do not often meet and sustain these rates. One reason for such failure might be that individual dog owners might feel that it is too expensive to vaccinate their pets. Recent estimates in the US of the cost of vaccinating dogs range from $US16 to $US24 per dog. In developing countries, estimates range from $US0.52 in Thailand, to $US1.19 in the Philippines, to $US2.70 in Malawi. None of these estimates include indirect costs accured by the pet owners. Lethal methods of dog population control are even more expensive, and attempting to control rabies by reducing dog populations has not worked for any extended period. Rabies in livestock is often reported, but the impact in the US and most developed countries appears relatively small. Vampire bat-transmitted rabies in Latin America appears to be the most serious rabies problem in livestock. The largest cost due to wildlife rabies is the cost of vaccinating domestic animals, both large and small. In the US, domestic animals face multiple sources of wildlife rabies. Attributing the entire cost of vaccinating domestic animals to 1 species can result in the over estimation of the benefits of immunising a given wildlife population via vaccine-laden baits. For example, despite a definite decline in the number of rabid foxes, it has been difficult to obtain the promised benefits of using oral vaccines in Europe to control fox rabies. Other authors maintain that the use of oral vaccines to control fox rabies is cost beneficial, but there are no convincing data supporting that claim. Additionally, vaccinating raccoons with an oral vaccine requires approximately 4 times more vaccine-laden baits vaccinating foxes, which makes it highly questionable if it would be cost beneficial to use oral vaccine to attempt raccoon rabies elimination in areas where it is already enzootic. The economics of using oral vaccines to prevent raccoon rabies invading uninfected areas has yet to be examined.

The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?

Understanding and quantifying the impact of a bioterrorist attack are essential in developing public health preparedness for such an attack. We constructed a model that compares the impact of three classic agents of biologic warfare (Bacillus anthracis, Brucella melitensis, and Francisella tularensis) when released as aerosols in the suburb of a major city. The model shows that the economic impact of a bioterrorist attack can range from an estimated $477.7 million per 100,000 persons exposed (brucellosis scenario) to $26.2 billion per 100,000 persons exposed (anthrax scenario). Rapid implementation of a postattack prophylaxis program is the single most important means of reducing these losses. By using an insurance analogy, our model provides economic justification for preparedness measures.

A possible explanation of the apparent breed-related resistance in cattle to bont tick (Amblyomma hebraeum) infestations.

Adult male Amblyomma hebraeum tick infestations and the weights of 20 Brahman steers and 38 Mashona heifers were measured at different periods at the Veterinary Quarantine Area at Mbizi, Zimbabwe. The experiment for the Brahmans lasted 108 weeks and that for the Mashona for 113 weeks. The Brahman steers weighed a maximum average of 478.4 kg (SE 7.9 kg), which was significantly different to the Mashona heifers maximum average of 391.4 kg (SE 5.6 kg) (P < 0.001). The Brahmans had a maximum average of 112.1 (SE 18.5) adult males, while the Mashona heifers had a maximum average of 59.8 (SE 4.3). The difference was statistically significant (P < 0.05). There was no statistical difference between the two maximum average ticks per kilogram liveweight (P > 0.05). When differences in size are corrected for, then breed-related differences disappear. It is emphasized that the influence of confounding factors, especially time, cannot be corrected for in a satisfactory manner. Therefore, these statistical results should be regarded as illustrative rather than proof. To confirm these results, it is suggested that the authors of earlier studies should reanalyze their databases in a similar manner. It is important that such analyses be conducted, or new experiments carried out. Erroneous conclusions regarding the reason for different tick numbers between the breeds could result in farmers being incorrectly encouraged to utilize smaller breeds to obtain 'built-in' resistance to A. hebraeum ticks. One logical explanation for the size-related effect is that the males typically attach themselves around the belly and groin areas. Larger breeds of cattle, such as the Brahman, will naturally have larger surface areas of skin in the belly and groin regions than smaller breeds. Thus, it is suggested that there may be a simple physical explanation for the difference between breeds in the numbers of attached adult A. hebraeum males.

Assessing the costs and benefits of an oral vaccine for raccoon rabies: a possible model.

Any cost-benefit analysis of the use of an oral vaccine to control raccoon rabies should include calculating both costs and benefits in terms of $/unit area. Further, cost savings must be adjusted to match the stages of an epizootic: pre-epizootic, epizootic, and post-epizootic. A generic model, which can be adapted to different sites, illustrates the use of threshold analysis to link distribution costs, cost savings, bait density, and vaccine price. Initial results indicate the need to lower the cost of the vaccine, continue research to determine optimal bait densities, and examine distribution plans that do not require continued protection of areas in which raccoon rabies was eliminated through previous vaccination programs.